Longeveron Announces Japanese Approval of Clinical Trial for Treatment of Aging Frailty With Longeveron’s Stem Cells – Yahoo Finance
stemadminStem Cell MedicineNo comments

The Phase 2 study will assess the safety and efficacy of Longeveron's stem cell treatment under Japan's accelerated regulatory pathway for regenerative medicine. MIAMI, June 1, 2020 /PRNewswire/ --Longeveron LLC announced today that Japan's Pharmaceutical and Medical Devices Agency (PMDA) (the Japanese agency akin to the United States' Food & Drug Administration) approved a Clinical Trial Notification (CTN) application (akin to an Investigational New Drug Application or "IND" in the US regulatory system), approving the initiation of a Phase 2 clinical trial evaluating the safety and efficacy of Longeveron's Mesenchymal Stem Cells (LMSCs) for the treatment of Aging Frailty in Japanese patients.

Read more
New Leaders at ASTCT and CIBMTR Provide Guidelines and Measures for Combating COVID-19 and Protecting Transplant Patients – Business Wire
stemadminStem Cell MedicineNo comments

CHICAGO--(BUSINESS WIRE)--The American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR) outlined today their guidelines and measures for combating the spread of COVID-19, while providing protection to transplant patients. The guidelines and measures include new practices for data collection, sharing of information, and administrative relief for facilities impacted by COVID-19 precautions

Read more
Hair regeneration using stem cells to treat baldness – BioNews
stemadminStem Cell MedicineNo comments

26 May 2020 Stem cells derived from fat can lead to hair regrowth for people with a common type of baldness, according to a new study. The South Korean researchersconducted a clinical trial into androgenetic alopecia (AGA), the most common cause of hair loss. The trial showed that the use of extracts of fat tissue termed adipose-derived stem cell constituent extract (ADSC-CE) increasedboth hair thickness and density in patients.

Read more
Potential Impact of Covid-19 Outbreak On Stem Cell Assay Market Business Outlook, Analysis and Forecast 2020 2027 to 2027 | Merck & Co., Thermo…
stemadminStem Cell MedicineNo comments

CMI announced that its published an exclusive report namely Global Stem Cell Assay Market by Manufacturers, Regions, Type and Application, Forecast to 2027 in its research database with report summary, table of content, research methodologies and data sources. The research study offers a substantial knowledge platform for entrants and investors as well as veteran companies, manufacturers functioning in the Worldwide Stem Cell Assay Market. This is an informative study covering the market with in-depth analysis and portraying the current state of affairs in the industry.

Read more
Regenerative Therapies: Helping Horses Self-Heal The Horse – TheHorse.com
stemadminStem Cell MedicineNo comments

The art (and existing science) of regenerative medicine in equine practice, and whats to come Regenerative therapy is an umbrellaterm encompassing any method that encourages the body to self- heal. Because it is drawing onits own properties, healing tissue more closely resembles native tissue than weak, disorganized scar tissue typically seen post-injury. The goal is to allow restoration of normal function and structure of the injured tissue to allow horses to perform at their previous level, whatever that might be, with a reduced risk of reinjury, says Kyla Ortved, DVM, PhD, Dipl

Read more
New human-mouse chimera is the most human yet – Livescience.com
stemadminStem Cell MedicineNo comments

A newly-created mouse-human embryo contains up to 4% human cells the most human cells yet of any chimera, or an organism made of two different sets of DNA. Surprisingly, those human cells could learn from the mouse cells and develop faster at the pace of a mouse embryo rather than a more slowly developing human embryo. That finding was "very serendipitous We did not really foresee that," said senior author Jian Feng, a professor in the department of physiology and biophysics at the State University of New York at Buffalo

Read more
High Rate of Responses Seen With Ide-cel in Heavily Pretreated Myeloma – Targeted Oncology
stemadminStem Cell MedicineNo comments

Treatment with idecabtagene vicleucel (ide-cel; bb2121) led to responses in 73% of heavily pretreated patients with relapsed or refractory multiple myeloma, and complete responses (CRs) in 33%, according to topline findings from the pivotal phase 2 KarMMA trial. Data shared during the 2020 ASCO Virtual Scientific Program demonstrated a median duration of response (DOR) of 10.7 months, and amedian progression-free survival (PFS) of 8.8 months (95% CI, 5.6-11.6). Ide-cel demonstrated frequent, deep, and durable responses in heavily pretreated, highly relapsed/refractory patients with myeloma, said Nikhil C.

Read more
COVID-19: Responding to the business impacts of Covid-19 Impact on Induced Pluripotent Stem Cells (iPSCs) Market-Segment Market Trends, Analysis and…
stemadminStem Cell MedicineNo comments

The global Covid-19 Impact on Induced Pluripotent Stem Cells (iPSCs) market study presents an all in all compilation of the historical, current and future outlook of the market as well as the factors responsible for such a growth. With SWOT analysis, the business study highlights the strengths, weaknesses, opportunities and threats of each Covid-19 Impact on Induced Pluripotent Stem Cells (iPSCs) market player in a comprehensive way. Further, the Covid-19 Impact on Induced Pluripotent Stem Cells (iPSCs) market report emphasizes the adoption pattern of the Covid-19 Impact on Induced Pluripotent Stem Cells (iPSCs) across various industries

Read more
Study reveals factors influencing outcomes in kidney cancer treated with immunotherapy – Science Codex
stemadminStem Cell MedicineNo comments

BOSTON - By analyzing tumors from patients treated with immunotherapy for advanced kidney cancer in three clinical trials, Dana-Farber Cancer Institute scientists have identified several features of the tumors that influence their response to immune checkpoint inhibitor drugs. The research was presented during the Clinical Science Symposium at the American Society of Clinical Oncology (ASCO) Annual Meeting and published simultaneously in Nature Medicine. The researchers say the study provides important clues about kidney cancer genetics and its interaction with the immune system that may prove to be vital in our ability to predict which patients are likely to benefit from immunotherapy drugs, which have been approved for first- and second-line treatment in the disease, but which don't work in all patients

Read more

Theme: Illdy.